ArchiMed MED Platform I Fund (MP I)

	Next higher product group	fund, biotech / life sciences
	Status	2020-08-01 start
	Annual sales	EUR 1,500,000,000 (fund size fully invested (2022) 2022)
	Document for annual sales	ArchiMed SAS. (10/7/22). "Press Release: ArchiMed Invests in PlasmidFactory, a German Gene and Cell Therapy Specialist".
	Organisation	ArchiMed MED Platform I Fund (MP I)
	Group	ArchiMed (Group)

ArchiMed SAS. (8/5/21). "Press Release: ArchiMed Closes MED III at €650 Million Hard Cap in Less than Two Months".

Raised entirely by virtual means, the healthcare fund was oversubscribed, receiving hard commitments in excess of €1.3 billion.

Leading private equity healthcare specialist ARCHIMED announces the one-and-done final close of its small cap-focused MED III fund on its upper limit of €650 million after less than two months of fundraising. The fund is twice the size of its predecessor, the fully invested MED II fund, which closed on €315 million in 2017. MED III targeted €500 million and received hard commitments in excess of €1.3 billion.

“Investors pushed us towards a significantly higher hard cap,” says ARCHIMED founder and Managing Partner, Denis Ribon. “But we wanted to stay true to the fund’s focus on smaller firms, so we capped this where it makes sense for the strategy. Investment discipline is key to our success and we’ve sized MED III to provide a seamless transition from MED II, based on a very strong deal pipeline.”

Over 95 percent of MED II investors re-upped. Some 25 percent of MED III investors – old and new – come from the United States, with 50 percent spread through most of the EU countries and the remainder from European countries outside the EU. Some 85 percent are institutional, mostly endowments, foundations, insurance companies and pension funds, while 15 percent are family offices. MED III was raised exclusively by virtual means, with no placement agent. Clifford Chance acted as legal advisor.

Using limited leverage so as not to compromise growth opportunities, MED III will target 12-14 majority control investments in healthcare companies with annual revenues of between €10 million and €100 million, in Europe and North America, partnering with families, founders and management teams. Prioritized healthcare industries include Biopharma and related services, Medtech, Life Sciences, Diagnostics, Consumer Health and Healthcare IT.

The latest fund’s predecessor, MED II, invested in a total of 11 companies and is a top quartile performer for global buyout funds for its vintage year, according to Preqin. ARCHIMED’s inaugural MED I fund, which raised €150 million in 2014, invested in nine companies and is currently ranked the best performing buyout fund on a global level for its vintage year, registering a total return in excess of six times invested capital (it’s already distributed more than four times invested capital to limited partners). ARCHIMED’s mid cap-focused MED Platform I fund, which held a final close on €1 billion last August, is now 70 percent invested.

About ARCHIMED

archimed.group

With offices in the US and Europe, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to North American and European healthcare businesses.

Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services.

ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ARCHIMED’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ARCHIMED manages €5 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

ARCHIMED Press Contacts

France: Stéphanie du Ché
stephanie.duche@archimed.group
+33 (0)6 16 36 11 08

International: David Lanchner
dlanchner@lanchner.com,
+33 (0)6 33 43 50 76